Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage

Recruiting Phase 4 Interventional Study
Postpartum Hemorrhage Twin Pregnancy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 4
Study type
Interventional
Purpose
Prevention
Participants needed
120 (estimated)
Sponsor
Sheba Medical Center · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if the drug carbetocin works better than standard care to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding after delivery, also called postpartum hemorrhage, is more common after twin births and can lead to anemia, blood transfusions, and other serious health problems. In this study, bleeding will be evaluated …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Pregnant individuals aged ≥18 years * Twin pregnancies * Gestational age ≥23 weeks Exclusion Criteria: * Known hypersensitivity or contraindication to carbetocin * Higher-order multiple gestation (triplets or more) * Maternal age \<18 years * Known placenta accreta spectrum …
Contacts

Avihu Krieger, MD

+972547421909

avihuey@gmail.com

CONTACT

Tal Cahan, MD

+972528305662

Tal.Cahan@sheba.health.gov.il

CONTACT